SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Mashington D.C. 20540

Washington, D.C. 20549

OMB APPROVAL

						APPROVAL	L
to Section 16.	x if no longer subjec Form 4 or Form 5 ay continue. <i>See</i> b).		ENT OF CHANGES IN BENEFICIAL OW Filed pursuant to Section 16(a) of the Securities Exchange Act of 19 or Section 30(h) of the Investment Company Act of 1940		OMB Number Estimated aver hours per resp	erage burden	5-0287 0.5
1. Name and Add Young Jona	Iress of Reporting I <mark>than</mark>	Person [*]	2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [AKRO]	5. Relationship of (Check all applica Director	able)	10% Owner	r
(Last) C/O AKERO	(First) THERAPEUTI	(Middle) CS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 11/17/2023	X Officer (below) Chie	give title	Other (spec below) Officer	uty
	Y BOULEVAI	RD, SUITE 350	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Jo Line) X Form file	int/Group Filing		cable
(Street) SOUTH SAN FRANCISCO	CA	94080	Rule 10b5-1(c) Transaction Indication	Person	ed by More than	One Reportin	g
(City)	(State)	(Zip)			on or written plan	that is intended	t to

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	11/17/2023		S		30,000	D	\$14.6753(1)	153,177	D	
Common Stock								20,000	I	By EA Irrevocable Trust ⁽²⁾
Common Stock								20,000	I	By CM Irrevocable Trust ⁽²⁾
Common Stock								20,000	Ι	By JL Irrevocable Trust ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Expiration Date		5. Date Exercisable and Expiration Date Month/Day/Year)		Amount of		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$14.50 to \$15.038, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.

2. These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	/s/ Jonathan Young	11/21/2023
--	--------------------	------------

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.